A novel vaccination strategy against Vibrio harveyi infection in Asian seabass (Lates calcarifer) with the aid of oxygen nanobubbles and chitosan.

Immersion vaccination, albeit easier to administer than immunization by injection, sometimes has challenges with antigen uptake, resulting in sub-optimal protection. In this research, a new strategy to enhance antigen uptake of a heat-inactivated Vibrio harveyi vaccine in Asian seabass (Lates calcarifer) using oxygen nanobubble-enriched water (ONB) and positively charged chitosan (CS) was explored. Antigen uptake in fish gills was assessed, as was the antibody response and vaccine efficacy of four different combinations of vaccine with ONB and CS, and two control groups. Pre-mixing of ONB and CS before introducing the vaccine, referred to as (ONB + CS) + Vac, resulted in superior antigen uptake and anti-V. harveyi antibody (IgM) production in both serum and mucus compared to other formulas. The integration of an oral booster (4.22 × 108 CFU/g, at day 21-25) within a vaccine trial experiment set out to further evaluate how survival rates post exposure to V. harveyi might be improved. Antibody responses were measured over 42 days, and vaccine efficacy was assessed through an experimental challenge with V. harveyi. The expression of immune-related genes IL1ß, TNFα, CD4, CD8, IgT and antibody levels were assessed at 1, 3, and 7-day(s) post challenge (dpc). The results revealed that antibody levels in the group (ONB + CS) + Vac were consistently higher than the other groups post immersion immunization and oral booster, along with elevated expression of immune-related genes after challenge with V. harveyi. Ultimately, this group demonstrated a significantly higher relative percent survival (RPS) of 63 % ± 10.5 %, showcasing the potential of the ONB-CS-Vac complex as a promising immersion vaccination strategy for enhancing antigen uptake, stimulating immunological responses, and improving survival of Asian seabass against vibriosis.

Systemic and mucosal antibody response of freshwater cultured Asian seabass (Lates calcarifer) to monovalent and bivalent vaccines against Streptococcus agalactiae and Streptococcus iniae.

Asian seabass, Lates calcarifer farming in Southeast Asia, encounters serious disease challenges caused by Streptococcus agalactiae and Streptococcus iniae. However, a vaccine for disease prevention is not yet available. In this study, we investigated the mucosal and systemic antibody (IgM) response kinetics of the Asian seabass following primary immunization with oil-based formalin-killed vaccines (FKVs) prepared from S. agalactiae and S. iniae (monovalent Sa, monovalent Si, and bivalent Sa-Si) and secondary booster with the respective water-based FKVs. The efficacy of vaccines was subsequently evaluated by an experimental challenge. The results revealed similar antibody response kinetics in both systemic and mucosal systems. However, the immune response in the fish vaccinated with the monovalent vaccines was superior to those fish received the bivalent vaccine in terms of specific antibody titer. The fish that received monovalent vaccines required 1-2 weeks to raise a significant level of specific antibody titer in both systemic and mucosal systems while those vaccinated with bivalent vaccine required three weeks. Following booster at day 21, both systemic and mucosal antibody titers in all vaccinated groups had reached the peak at day 28 and gradually declined in the following weeks but remained significantly higher than control until the end of the experiment (day 63). In the challenge test, both monovalent and bivalent vaccines were found to be highly efficacious, with the relative percentage survival (RPS) ranging from 75 to 85%. In summary, this study explored the 63-days antibody response kinetics (both mucosal and systemic systems) of Asian seabass to monovalent and bivalent inactivated vaccines and confirmed that the combination of S. agalactiae and S. iniae in a single injectable vaccine is possible.